SYK vs. BSX, BDX, DXCM, SNY, ISRG, ELV, PFE, AMGN, MDT, and CI
Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Boston Scientific (BSX), Becton, Dickinson and Company (BDX), DexCom (DXCM), Sanofi (SNY), Intuitive Surgical (ISRG), Elevance Health (ELV), Pfizer (PFE), Amgen (AMGN), Medtronic (MDT), and The Cigna Group (CI). These companies are all part of the "medical" sector.
Boston Scientific (NYSE:BSX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Boston Scientific received 108 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.31% of users gave Boston Scientific an outperform vote while only 64.49% of users gave Stryker an outperform vote.
In the previous week, Boston Scientific had 28 more articles in the media than Stryker. MarketBeat recorded 64 mentions for Boston Scientific and 36 mentions for Stryker. Boston Scientific's average media sentiment score of 0.84 beat Stryker's score of 0.43 indicating that Stryker is being referred to more favorably in the news media.
Stryker has a net margin of 16.03% compared to Stryker's net margin of 12.06%. Boston Scientific's return on equity of 23.44% beat Stryker's return on equity.
89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.5% of Boston Scientific shares are held by company insiders. Comparatively, 5.9% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Boston Scientific has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Boston Scientific currently has a consensus target price of $75.09, suggesting a potential upside of 3.99%. Stryker has a consensus target price of $363.67, suggesting a potential upside of 10.83%. Given Boston Scientific's higher probable upside, analysts clearly believe Stryker is more favorable than Boston Scientific.
Summary
Stryker beats Boston Scientific on 10 of the 19 factors compared between the two stocks.
Get Stryker News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
